Bioxcel therapeutics reports fourth quarter and full year 2022 financial results and recent operational highlights

Igalmi™ (dexmedetomidine) commercial execution fully underway in 2023 with key focus on market access and demand generation through expanded field team

BTAI Ratings Summary

BTAI Quant Ranking